[1] 钱建丹,李俊,霍娜,等.《拯救脓毒症运动:2021年脓毒症和脓毒症休克管理国际指南》感染管理更新要点解读[J].中华传染病杂志,2022,40(7):385-391. [2] 郝明伟,吴凤玲,杨薛萍,等.脓毒性休克患者并发AKI的影响因素及miR-21与miR-29a对预后的评估价值[J].中华医院感染学杂志,2021,31(20):3041-3045. [3] Yajnik V,Maarouf R.Sepsis and the microcirculation:the impact on outcomes[J].Curr Opin Anaesthesiol,2022,35(2):230-235. [4] 陈彦霖.基于多器官衰竭相关性和特征动态变化的脓毒症预测[D].上海:上海财经大学,2022. [5] 凌杰兵,马斌.可溶性sCD14-ST及CD14+单核细胞在老年ICU脓毒症患者早期诊断和评估中的价值[J].中国老年学杂志,2022,42(20):5042-5045. [6] Juan CX,Mao Y,Cao Q,et al.Exosome-mediated pyroptosis of miR-93-TXNIP-NLRP3 leads to functional difference between M1 and M2 macrophages in sepsis-induced acute kidney injury[J].Cell Mol Med,2021,25(10):4786-4799. [7] 邱泽亮.外源性铁调素在脓毒症急性肾损伤中的作用及机制研究[D].江苏:苏州大学,2022. [8] 陈荣鑫.GPR55拮抗剂CID16020046通过调控炎症和细胞凋亡改善脓毒症小鼠急性肾损伤[D].广东:广州医科大学,2022. [9] 许英珠,文晓宏,卢运生.血清IL-17、IL-18联合检测对脓毒症并发急性肾损伤的诊断价值[J].临床与病理杂志,2022,42(12):2884-2889. [10] 杨珊,贾文.脓毒症患儿尿肝型脂肪酸结合蛋白、血清热休克蛋白72水平检测对早期急性肾损伤及预后的评估价值[J].儿科药学杂志,2023,29 (7):36-40. [11] 王娜,秦卓,刘慧珍,等.营养风险评分对脓毒症相关性急性肾损伤患者预后的临床价值[J].中华危重病急救医学,2022,34(3):245-249. [12] Santos RPD,Carvalho ARDS,Peres LAB,et al.Non-recovery of renal function is a strong independent risk factor associated with mortality in AKI patients[J].J Bras Nefrol,2020,42(3):290-299. [13] Matsuura R,Doi K,Hamasaki Y,et al.RRT selection for AKI patients with critical illness[J].Semin Nephrol,2020,40(5):498-505. [14] 于楠,高莹,张俊清.从SARS到COVID-19-血管紧张素转化酶2在冠状病毒感染致高血糖中作用的探讨[J].中国糖尿病杂志,2020,28(3):172-175. [15] 王新蕊.去甲肾上腺素联合血管加压素对脓毒症相关急性肾损伤预后的影响[D].河北:河北医科大学,2022. [16] Zhan F,Wang X,Zhang J,et al.Glutamine alleviates the renal dysfunction associated with gentamicin-induced acute kidney injury in sprague-dawley rats[J].Biotechnol Appl Biochem,2022,69(1):323-329. [17] 李桂仙,潘兴邦,顾伟.可溶性白细胞介素7受体联合其他生物标志物对急诊脓毒症的诊断价值[J].中国医师杂志,2023,25(3):388-392. |